DuVax Vaccines and Reagents Inc. was formed in January of 2011 to further develop and market a platform technology which will be used to produce a line of highly protective, safe, and cost effective vaccines and biological reagents. This proprietary technology isolates the essential genes naturally occurring in Arctic bacteria and utilizes these genes within bacterial pathogens to construct stable, temperature-sensitive live bacterial vaccines. Patent protection is being sought in several jurisdictions, including U.S., Canada, Europe, Brazil, China and Australia. Of significance is the fact that this technology has the ability to facilitate the production of live attenuated temperature-sensitive vaccines for almost any bacterial species. Detailed findings were recently published in the July 2010 edition of the Proceedings of the National Academy of Sciences and can be viewed at www.pnas.org/content/107/30/13456.